Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients

被引:22
作者
Gounaris, I. [1 ]
Provenzano, E. [2 ,3 ]
Vallier, A. L. [1 ,2 ]
Hiller, L. [4 ]
Iddawela, M. [1 ,2 ]
Hilborne, S. [2 ]
Taylor, K. [2 ]
Britton, P. [2 ,3 ]
Earl, H. M. [1 ,3 ,5 ]
Sinnatamby, R. [3 ]
机构
[1] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 0QQ, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge Breast Unit, Cambridge CB2 2QQ, England
[3] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge CB2 0QQ, England
[4] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England
[5] Univ Cambridge, Dept Oncol, Cambridge CB2 0QQ, England
关键词
Breast cancer; Neoadjuvant chemotherapy; Volumetric ultrasound; Pathological response; TUMOR RESPONSE; MAMMOGRAPHY; ULTRASONOGRAPHY; SONOGRAPHY; WOMEN; DOXORUBICIN; TOMOGRAPHY; SIZE;
D O I
10.1007/s10549-011-1454-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurements prior to, after 4 cycles (mid-treatment), and at the end of 8 cycles (end-treatment) of chemotherapy were available from a subset of 55 patients enrolled in Neo-tAnGo, a National Cancer Research Network (NCRN) UK neoadjuvant chemotherapy breast cancer trial. Proportional changes in longest diameter (LD) and volume as well as absolute residual size thresholds were examined for their ability to predict pCR or pCR plus minimal residual disease (pCR/MRD). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) and likelihood ratios (LRs) were calculated. Receiver-operator characteristic (ROC) curves and logistic regression models were also constructed. At mid-treatment, neither complete radiological response, nor proportional LD or volume changes were found predictive of final pCR. A small residual tumour volume (a parts per thousand currency sign1 cm(3) vs. > 1 cm(3)) at mid-treatment, however, was associated with pCR/MRD (P = 0.014). Sensitivity, specificity, PPV, NPV, LR+ and LR- values were 61%, 77%, 61%, 77%, 2.62 and 0.51, respectively. The area under the ROC curve was 0.689 (P = 0.03). Volume a parts per thousand currency sign1 cm(3) at mid-treatment was found significant in a logistic regression (OR: 0.194, P = 0.011). At end-treatment, no ultrasound measurements were found predictive of pCR or pCR/MRD. In conclusion, proportional tumour size changes (the basis of the RECIST criteria) were not found predictive of good pathological response, although residual volume a parts per thousand currency sign1 cm(3) at mid-treatment was found to be predictive of pCR/MRD. However, multiple volume and LD thresholds were examined and uncorrected P values presented, increasing the possibility of type I errors. Replication in an independent dataset is required.
引用
收藏
页码:459 / 469
页数:11
相关论文
共 35 条
[11]   Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease [J].
Fiorentino, C ;
Berruti, A ;
Bottini, A ;
Bodini, M ;
Brizzi, MP ;
Brunelli, A ;
Marini, U ;
Allevi, G ;
Aguggini, S ;
Tira, A ;
Alquati, P ;
Olivetti, L ;
Dogliotti, L .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (02) :143-151
[12]   ULTRASONOGRAPHY AS A METHOD OF MEASURING BREAST-TUMOR SIZE AND MONITORING RESPONSE TO PRIMARY SYSTEMIC TREATMENT [J].
FOROUHI, P ;
WALSH, JS ;
ANDERSON, TJ ;
CHETTY, U .
BRITISH JOURNAL OF SURGERY, 1994, 81 (02) :223-225
[13]  
Herrada J, 1997, CLIN CANCER RES, V3, P1565
[14]  
Huber S, 2000, J ULTRAS MED, V19, P677
[15]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[16]   Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic Imaging in primary breast cancer patients [J].
Kanazawa, T ;
Akashi-Tanaka, S ;
Iwamoto, E ;
Takasugi, M ;
Shien, T ;
Kinoshita, T ;
Miyakawa, K ;
Shimizu, C ;
Ando, M ;
Katsumata, N ;
Fujiwara, Y ;
Fukutomi, T .
BREAST JOURNAL, 2005, 11 (05) :311-316
[17]   Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer [J].
Keune, Jason D. ;
Jeffe, Donna B. ;
Schootman, Mario ;
Hoffman, Abigail ;
Gillanders, William E. ;
Aft, Rebecca L. .
AMERICAN JOURNAL OF SURGERY, 2010, 199 (04) :477-484
[18]   Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J].
Kuerer, HM ;
Newman, LA ;
Smith, TL ;
Ames, FC ;
Hunt, KK ;
Dhingra, K ;
Theriault, RL ;
Singh, G ;
Binkley, SM ;
Sneige, N ;
Buchholz, TA ;
Ross, MI ;
McNeese, MD ;
Buzdar, AU ;
Hortobagyi, GN ;
Singletary, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :460-469
[19]  
LI SI, 2007, CANCER EPIDEM BIOMAR, V16, P2773
[20]   Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy [J].
Londero, V ;
Bazzocchi, M ;
Del Frate, C ;
Puglisi, F ;
Di Loreto, C ;
Francescutti, G ;
Zuiani, C .
EUROPEAN RADIOLOGY, 2004, 14 (08) :1371-1379